Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2023 Jan 11

PMID 36630138

Authors

Raymond L Barnhill

David E Elder

Michael W Piepkorn

Stevan R Knezevich

Lisa M Reisch

Megan M Eguchi

Boris C Bastian

Willeke Blokx

Marcus Bosenberg

Klaus J Busam

Richard Carr

Alistair Cochran

Martin G Cook

Lyn M Duncan

Rosalie Elenitsas

Arnaud De la Fouchardiere

Pedram Gerami

Iva Johansson

Jennifer Ko

Gilles Landman

Alexander J Lazar

Lori Lowe

Daniela Massi

Jane Messina

Daniela Mihic-Probst

Douglas C Parker

Birgitta Schmidt

Christopher R Shea

Richard A Scolyer

Michael Tetzlaff

Xiaowei Xu

Iwei Yeh

Artur Zembowicz

Joann G Elmore

Affiliations

Soon will be listed here.

Abstract

Importance: A standardized pathology classification system for melanocytic lesions is needed to aid both pathologists and clinicians in cataloging currently existing diverse terminologies and in the diagnosis and treatment of patients. The Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) has been developed for this purpose.

Objective: To revise the MPATH-Dx version 1.0 classification tool, using feedback from dermatopathologists participating in the National Institutes of Health-funded Reducing Errors in Melanocytic Interpretations (REMI) Study and from members of the International Melanoma Pathology Study Group (IMPSG).

Evidence Review: Practicing dermatopathologists recruited from 40 US states participated in the 2-year REMI study and provided feedback on the MPATH-Dx version 1.0 tool. Independently, member dermatopathologists participating in an IMPSG workshop dedicated to the MPATH-Dx schema provided additional input for refining the MPATH-Dx tool. A reference panel of 3 dermatopathologists, the original authors of the MPATH-Dx version 1.0 tool, integrated all feedback into an updated and refined MPATH-Dx version 2.0.

Findings: The new MPATH-Dx version 2.0 schema simplifies the original 5-class hierarchy into 4 classes to improve diagnostic concordance and to provide more explicit guidance in the treatment of patients. This new version also has clearly defined histopathological criteria for classification of classes I and II lesions; has specific provisions for the most frequently encountered low-cumulative sun damage pathway of melanoma progression, as well as other, less common World Health Organization pathways to melanoma; provides guidance for classifying intermediate class II tumors vs melanoma; and recognizes a subset of pT1a melanomas with very low risk and possible eventual reclassification as neoplasms lacking criteria for melanoma.

Conclusions And Relevance: The implementation of the newly revised MPATH-Dx version 2.0 schema into clinical practice is anticipated to provide a robust tool and adjunct for standardized diagnostic reporting of melanocytic lesions and management of patients to the benefit of both health care practitioners and patients.

Citing Articles

Dysplastic Nevi and Superficial Borderline Atypical Melanocytic Lesions: Description of an Algorithmic Clinico-Pathological Classification.

Menzinger S, Merat R, Kaya G Dermatopathology (Basel). 2025; 12(1).

PMID: 39982351 PMC: 11860396. DOI: 10.3390/dermatopathology12010003.

Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study.

Wu Z, Nickel B, Boroumand F, Elder D, Ferguson P, Scolyer R BMJ Open. 2025; 14(12):e089558.

PMID: 39806624 PMC: 11667480. DOI: 10.1136/bmjopen-2024-089558.

The 2023 WHO updates on skin tumors: advances since the 2018 edition.

Fortarezza F, Cazzato G, Ingravallo G, Dei Tos A Pathologica. 2024; 116(4):193-206.

PMID: 39377501 PMC: 11460152. DOI: 10.32074/1591-951X-1006.

Natural language processing in dermatology: A systematic literature review and state of the art.

Paganelli A, Spadafora M, Navarrete-Dechent C, Guida S, Pellacani G, Longo C J Eur Acad Dermatol Venereol. 2024; 38(12):2225-2234.

PMID: 39150311 PMC: 11587683. DOI: 10.1111/jdv.20286.

Robust ROI Detection in Whole Slide Images Guided by Pathologists' Viewing Patterns.

Ghezloo F, Chang O, Knezevich S, Shaw K, Thigpen K, Reisch L J Imaging Inform Med. 2024; 38(1):439-454.

PMID: 39122892 PMC: 11811336. DOI: 10.1007/s10278-024-01202-x.

References

Swerlick R, Chen S . The melanoma epidemic. Is increased surveillance the solution or the problem?. Arch Dermatol. 1996; 132(8):881-4. DOI: 10.1001/archderm.132.8.881. View

Fleming N, Egbert B, Kim J, Swetter S . Reexamining the Threshold for Reexcision of Histologically Transected Dysplastic Nevi. JAMA Dermatol. 2016; 152(12):1327-1334. DOI: 10.1001/jamadermatol.2016.2869. View

Guitart J, Lowe L, Piepkorn M, Prieto V, Rabkin M, Ronan S . Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002; 138(5):603-8. DOI: 10.1001/archderm.138.5.603. View

Corona R, Mele A, Amini M, De Rosa G, Coppola G, Piccardi P . Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996; 14(4):1218-23. DOI: 10.1200/JCO.1996.14.4.1218. View

Semsarian C, Ma T, Nickel B, Scolyer R, Ferguson P, Soyer H . Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?. Br J Dermatol. 2022; 186(6):1030-1032. PMC: 9546461. DOI: 10.1111/bjd.21010. View

Welch H, Woloshin S, Schwartz L . Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005; 331(7515):481. PMC: 1199022. DOI: 10.1136/bmj.38516.649537.E0. View

Piepkorn M, Eguchi M, Barnhill R, Elder D, Kerr K, Knezevich S . Reproducibility of the histopathologic diagnosis of melanoma and related melanocytic lesions: Results from a testing study and a reference guide for providers. JAAD Int. 2022; 9:7-10. PMC: 9391572. DOI: 10.1016/j.jdin.2022.06.017. View

BRESLOW A . Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970; 172(5):902-8. PMC: 1397358. DOI: 10.1097/00000658-197011000-00017. View

Soleymani T, Swetter S, Hollmig S, Aasi S . Adequacy of conservative 2- to 3-mm surgical margins for complete excision of biopsy-proven severely dysplastic nevi: Retrospective case series at a tertiary academic institution. J Am Acad Dermatol. 2020; 83(1):254-255. DOI: 10.1016/j.jaad.2019.12.077. View

10.

Cook M, Clarke T, Humphreys S, Fletcher A, McLaren K, Smith N . The evaluation of diagnostic and prognostic criteria and the terminology of thin cutaneous malignant melanoma by the CRC Melanoma Pathology Panel. Histopathology. 1996; 28(6):497-512. DOI: 10.1046/j.1365-2559.1996.d01-464.x. View

11.

Ronan S, Eng A, BRIELE H, Shioura N, Das Gupta T . Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987; 123(10):1326-30. View

12.

Fleming N, Shaub A, Bailey E, Swetter S . Outcomes of surgical re-excision versus observation of severely dysplastic nevi: A single-institution, retrospective cohort study. J Am Acad Dermatol. 2019; 82(1):238-240. DOI: 10.1016/j.jaad.2019.07.033. View

13.

Katz I, OBrien B, Clark S, Thompson C, Schapiro B, Azzi A . Assessment of a Diagnostic Classification System for Management of Lesions to Exclude Melanoma. JAMA Netw Open. 2021; 4(12):e2134614. PMC: 8665368. DOI: 10.1001/jamanetworkopen.2021.34614. View

14.

Lee S, Barnhill R, Dummer R, Dalton J, Wu J, Pappo A . TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015; 5:11200. PMC: 4462090. DOI: 10.1038/srep11200. View

15.

Ebbelaar C, Jansen A, Bloem L, Blokx W . Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis. Virchows Arch. 2021; 479(4):773-783. PMC: 8516778. DOI: 10.1007/s00428-021-03095-5. View

16.

Shain A, Bastian B . From melanocytes to melanomas. Nat Rev Cancer. 2016; 16(6):345-58. DOI: 10.1038/nrc.2016.37. View

17.

Ebbelaar C, Schrader A, van Dijk M, Meijers R, de Leng W, Bloem L . Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing. Mod Pathol. 2022; 35(8):1110-1120. DOI: 10.1038/s41379-022-01026-6. View

18.

Clark Jr W, Elder D, Guerry 4th D, Braitman L, Trock B, Schultz D . Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81(24):1893-904. DOI: 10.1093/jnci/81.24.1893. View

19.

Piepkorn M, Barnhill R, Elder D, Knezevich S, Carney P, Reisch L . The MPATH-Dx reporting schema for melanocytic proliferations and melanoma. J Am Acad Dermatol. 2013; 70(1):131-41. PMC: 3992990. DOI: 10.1016/j.jaad.2013.07.027. View

20.

Tsao H, Bevona C, Goggins W, Quinn T . The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol. 2003; 139(3):282-8. DOI: 10.1001/archderm.139.3.282. View